Company intelligence / Profile preview
Ting Therapeutics
San Diego, California, United Statestingtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has characterized a drug called piplartine (TT003) that protects against antibiotics-induced hearing loss in zebrafish and mice as early proof-of-concept data. This work was supported by an NIH SBIR phase I grant which has been extended to a phase II grant to develop TT003.[3]
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesrepurposed FDA-approved drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Ting Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ting Therapeutics.